Literature DB >> 20207711

Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function.

Jung Pyo Lee1, Nam Ju Heo, Kwon Wook Joo, Nam Joon Yi, Kyung-Suk Suh, Kyung Chul Moon, Seong Gyun Kim, Yon Su Kim.   

Abstract

BACKGROUND: Chronic kidney disease (CKD) develops frequently after liver transplantation (LTx), and it is important to identify and correct risk factors that negatively affect kidney function. Risk factors have not been well evaluated in Asian countries where hepatitis B virus (HBV) infection is a dominant cause.
METHODS: Four hundred thirty-one Korean recipients who underwent LTx between 1997 and 2008 were analysed. CKD was defined as a sustained decrease in estimated glomerular filtration rate (eGFR) of <60 (mL/min/1.73 m(2)) for at least three consecutive months using an abbreviated Modification in Renal Disease (MDRD) formula.
RESULTS: Eighty percent of the patients had HBV-related underlying diseases. The recipients whose pretransplant eGFR had been low (<30 mL/min/1.73 m(2)) improved their renal function after LTx, but significant functional decline occurred in recipients whose pretransplant eGFR was high (>or=60 mL/min/1.73 m(2)). A multivariate Cox regression analysis revealed that the overall risk of CKD development (eGFR < 60 mL/min/1.73 m(2)) was associated with old age of recipients, cyclosporine, posttransplant acute renal failure (ARF), cause [calcineurin inhibitor (CNI) nephrotoxicity] and severity of posttransplant ARF, low pretransplant eGFR, pretransplant hepatorenal syndrome, pretransplant proteinuria, high Child-Pugh score and high Model for End-Stage Renal Disease (MELD) score. Especially in recipients whose pre-operative eGFR was high (>or=60 mL/min/1.73 m(2)), rapid progression of kidney disease was associated with high tacrolimus level, non-HBV disease, posttransplant ARF, cause (CNI nephrotoxicity) and severity of posttransplant ARF and Child-Pugh score. CNI toxicity and focal segmental sclerosis, but not immune-complex disease, were revealed as significant contributors to CKD after LTx in HBV recipients.
CONCLUSION: Judicious use of CNIs should be applied to liver recipients to prevent kidney dysfunction.

Entities:  

Mesh:

Year:  2010        PMID: 20207711     DOI: 10.1093/ndt/gfq093

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.

Authors:  Zhen-Yong Shao; Lu-Nan Yan; Wen-Tao Wang; Bo Li; Tian-Fu Wen; Jia-Yin Yang; Ming-Qing Xu; Ji-Chun Zhao; Yong-Gang Wei
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 2.  Hepatorenal syndrome: Update on diagnosis and treatment.

Authors:  Olga Baraldi; Chiara Valentini; Gabriele Donati; Giorgia Comai; Vania Cuna; Irene Capelli; Maria Laura Angelini; Maria Ilaria Moretti; Andrea Angeletti; Fabio Piscaglia; Gaetano La Manna
Journal:  World J Nephrol       Date:  2015-11-06

Review 3.  Pre-transplant kidney function predicts chronic kidney disease after liver transplant: meta-analysis of observational studies.

Authors:  Fabrizio Fabrizi; Vivek Dixit; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2011-01-08       Impact factor: 3.199

4.  Risk factors for new-onset chronic kidney disease in patients who have received a liver transplant.

Authors:  Yuehong Li; Binbin Li; Wei Wang; Jiaxuan Lv
Journal:  Exp Ther Med       Date:  2018-01-31       Impact factor: 2.447

5.  Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010.

Authors:  Zhenhua Hu; Jie Zhou; Haibo Wang; Min Zhang; Shaogang Li; Yuzhou Huang; Jian Wu; Zhiwei Li; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

Review 6.  Hepatorenal Syndrome: Physiology, Diagnosis and Management.

Authors:  Joseph Chmielewski; Robert J Lewandowski; Haripriya Maddur
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

7.  Sluggish decline in a post-transplant model for end-stage liver disease score is a predictor of mortality in living donor liver transplantation.

Authors:  Won Jung Hwang; Joon Pyo Jeon; Seung Hee Kang; Hyun Sik Chung; Ji Yong Kim; Chul Soo Park
Journal:  Korean J Anesthesiol       Date:  2010-09-20

8.  Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation.

Authors:  M Sterneck; G M Kaiser; N Heyne; N Richter; F Rauchfuss; A Pascher; P Schemmer; L Fischer; C G Klein; S Nadalin; F Lehner; U Settmacher; P Neuhaus; D Gotthardt; M Loss; S Ladenburger; E M Paulus; M Mertens; H J Schlitt
Journal:  Am J Transplant       Date:  2014-02-06       Impact factor: 8.086

9.  Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.

Authors:  G B Klintmalm; S Feng; J R Lake; H E Vargas; T Wekerle; S Agnes; K A Brown; B Nashan; L Rostaing; S Meadows-Shropshire; M Agarwal; M B Harler; J-C Garcia-Valdecasas
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

10.  Peritoneal Dialysis After Liver Transplantation: A Systematic Review.

Authors:  Jean Maxime Côté; Isabelle Ethier; Héloïse Cardinal; Marie-Noëlle Pépin
Journal:  Can J Kidney Health Dis       Date:  2021-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.